ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1424	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	positive predictive value 0.503935 Needle aspiration cytology 0.492344 10-year survival rates 0.485559 hepatitis B virus 0.608203 hepatitis G infection 0.516552 control group 0.576587 6-monthly AFP assays 0.575205 North America 0.429041 nonalcoholic steatohepatitis 0.42282 AFP screening 0.526835 usual-care group 0.429439 ethnic groups 0.421496 test result 0.419937 HCC 0.942449 screening group 0.63461 Age-standardized incidence rates 0.541219 hepatitis B infection 0.498394 glycogen storage disease 0.517803 porphyria cutanea tarda 0.523911 new cases 0.427232 patients experience pain 0.502381 Serum AFP 0.49956 fetal-specific glycoprotein antigen 0.51455 United States 0.614175	screening tests 0.450593 retrospective case-control study 0.516703 mortality rate ratio 0.509505 certain Aspergillus species 0.510442 widely used tumor 0.501438 cryptogenic cirrhosis 0.452869 earlier diagnosis 0.555097 right upper quadrant 0.485875 common cancer 0.432709 surface antigen–positive carriers 0.524371 diagnosis study designs. 0.509206 Chinese Americans 0.422068 high incidence 0.419907 distinct male preponderance 0.54002 risk factor 0.421115 HCC mortality 0.712636 mortality rate 0.512472 randomized controlled trial 0.492498 alcoholic cirrhosis 0.45216 chronic hepatitis 0.816099 germ cell tumors 0.509004 liver biopsy 0.576034 annual risk 0.42449 liver cancer 0.48682	CLICK HERE
1453	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	population-based case-controlled study 0.456088 Incidence rates 0.385333 symptomatic gastroesophageal reflux 0.449595 Barrett epithelium 0.458468 control group 0.467545 population attributable risk 0.450158 abnormal intestinal-type epithelium 0.466177 upper gastrointestinal hemorrhage 0.4271 GERD symptoms 0.44816 dysplastic Barrett esophagus 0.622479 distal esophagus 0.516913 case-control studies 0.466408 characteristic endoscopic appearance 0.435919 racial/ethnic groups 0.387576 alcohol abuse 0.441548 sham ablation 0.397202 patients 0.529714 incidence rate 0.442768 relative risk 0.448332 long-standing GERD 0.393778 esophageal adenocarcinoma 0.436843 esophageal adenocarcinoma. 0.389793 Retrospective cohort studies 0.444668 radiofrequency ablation 0.397459	new cases 0.385134 population-based cohort study 0.450776 esophageal cancer 0.543708 United States 0.381547 neoplastic alteration 0.380441 squamous epithelium. 0.390253 Barrett esophagus 0.930056 disease progression 0.441468 low-grade dysplasia 0.40734 significantly increased risk 0.448898 recurrent reflux symptoms 0.445059 important epidemiological difference 0.443496 black men 0.381968 case-control study 0.397548 high-grade dysplasia group 0.469185 adenocarcinoma 0.464553 certain GERD symptoms 0.4422 risk factor 0.383382 randomized controlled trial 0.433019 treatment group 0.414938 stratified squamous epithelium 0.484787 ablation group 0.497322 risk 0.45334 columnar epithelium 0.407571	CLICK HERE
1562	National Cancer Institute	Html	en	Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of hypopharyngeal cancer.	cancer treatment 0.321266 high-dose radiation therapy 0.323579 centimeters 0.269921 cancer spreads 0.270417 malignant tumor cells 0.281954 body 0.305644 chemotherapy 0.290118 PDQ cancer information 0.346817 stage III hypopharyngeal 0.274417 clinical trial search 0.347149 clinical trials 0.698171 hypopharynx 0.280224 cancer information summary 0.319294 metastatic hypopharyngeal cancer 0.310093 clinical trial 0.551798 Recurrent hypopharyngeal cancer 0.306668 patients 0.317052 stage IV hypopharyngeal 0.274937 nearby soft tissue 0.271159 treatment clinical trial 0.275593 NCI PDQ cancer 0.283768 radiation therapy 0.705932 Treatment Editorial Board 0.281401 General information 0.289657 hypopharyngeal cancer 0.722179	general cancer information 0.275426 treatment 0.442202 new cancer treatments 0.272872 NCI-supported cancer 0.296123 cancer cells 0.361641 Cancer Information Service 0.276024 patient 0.26688 lymph nodes 0.350794 treatment clinical trials 0.300384 National Cancer Institute 0.364736 swollen lymph nodes 0.277694 new treatment 0.302418 External radiation therapy 0.314938 neck 0.309398 cancer research process 0.269057 cancer clinical trials 0.358746 stage 0.310003 neck cancer 0.286172 lymph node 0.322344 cancer information summaries 0.27414 comprehensive cancer information 0.274558 cancer 0.901171 standard treatment 0.274055 Hypopharyngeal Cancer Treatment 0.314822	CLICK HERE
1664	National Cancer Institute	Html	en	Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood atypical teratoid/rhabdoid tumors	cancer treatment 0.542006 metastatic brain tumors 0.391418 ongoing clinical trials 0.389415 PDQ cancer information 0.511527 tumor suppressor genes 0.452709 clinical trial search 0.399694 brain tumors 0.444671 CNS atypical teratoid/rhabdoid 0.388691 clinical trials 0.847224 Pediatric Treatment Editorial 0.416481 Teratoid/Rhabdoid Tumor Treatment 0.445097 cancer information summary 0.463674 clinical trial 0.521041 cancer cells 0.510172 stem cell transplant 0.396934 patients 0.411179 primary brain tumors 0.3918 treatment clinical trial 0.409064 NCI PDQ cancer 0.42324 radiation therapy 0.555658 Treatment Editorial Board 0.420841 Cord Tumors Treatment 0.414346 late effects 0.393798 treatment 0.689522 new cancer treatments 0.395428	PDQ treatment summary 0.447943 childhood brain 0.385451 Cancer Information Service 0.399251 specific cancer cells 0.397642 PDQ Pediatric Treatment 0.40786 treatment clinical trials 0.444124 National Cancer Institute 0.458723 spinal cord 0.616147 tumor cells 0.437516 effects cancer treatment 0.421518 new treatment 0.427513 childhood cancer information 0.400212 External radiation therapy 0.395094 brain tumor 0.405279 brain 0.467984 atypical teratoid/rhabdoid tumor 0.982554 PDQ summary 0.439127 cancer clinical trials 0.434177 cancer information summaries 0.39809 comprehensive cancer information 0.397631 cancer 0.740574 appropriate cancer treatment 0.419383 standard treatment 0.391688 fast-growing tumor 0.388774	CLICK HERE
1883	National Cancer Institute	Html	es	Tratamiento de los tumores extracraneales de células germinativas en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores extracraneales de células germinativas en la niñez.	cell tumor protocols 0.408279 germinativas malignas localización 0.405353 células germinativas seminomatosos.Seminoma 0.410393 cell tumor combined 0.407867 germ cell tumours 0.412186 Perlman EJ 0.405253 Calaminus G 0.412513 Cell Cancer Collaborative 0.406794 cell tumors from 0.406747 Göbel U 0.406021 Cancer Group 0.42074 cell tumor studies 0.407558 pediatric oncology 0.41388 células germinativas mixtos 0.417539 International Germ Cell 0.417008 Children's Oncology Group 0.409014 mediastinal germ 0.406328 cell tumor study 0.408368 <2 cm 0.405406 Metástasis peritoneales macroscópicas 0.405941 germ cell neoplasms 0.406391 Children's Cancer 0.42175 cell tumors show 0.406094 pediatric germ 0.426106 adultos jóvenes 0.40725	estadio iv 0.405826 ganglios linfáticos ≥2 0.411723 Germ Cell Consensus 0.412507 Cushing B 0.405386 teratomas benignos 0.407141 Genes Chromosomes Cancer 0.438953 with germ 0.406335 malignant germ cell 0.462527 PDQ Tratamiento 0.405882 childhood germ 0.409831 cell tumors based 0.405903 Clin Oncol 0.444548 saco vitelino 0.435575 linfáticos ≥2 cm 0.408554 Schneider DT 0.409517 Children's Cancer Group 0.419331 Cell Consensus Classification 0.409901 germ cell tumors 0.974328 Kingdom Children Cancer 0.408316 germ cell cancer 0.410294 Children's Cancer Study 0.409136 pediatric oncology group 0.410202 oncology group 0.420408 Cancer Study Group 0.411644	CLICK HERE
2000	National Cancer Institute	Html	es	Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la histiocitosis de células de Langerhans.	cuánto aire 0.415134 siguientes procedimientos 0.528715 células madre 0.858073 adultos jóvenes 0.464664 efectos secundarios meses 0.439126 siguientes aspectos 0.434701 faja ajustadora 0.428231 HCL infantil multisistémica 0.546722 cuántos sistemas 0.518567 genes ras 0.453948 pequeña cantidad 0.423844 células normales.ampliar exploración 0.532323 vía oral 0.42013 rayos x 0.425227 gen braf 0.666188 largo plazo 0.44968 cuántas células 0.518957 niño ayuda 0.426203 efectos tardíos 0.516221 escáner.ampliar exploración 0.429231 tarde.ampliar ecografía 0.427113	vías respiratorias 0.424871 causa problemas 0.424997 lesiones óseas 0.423193 National Cancer Institute 0.417904 IRMN).Ampliar Imágenes 0.421648 siguientes riesgos 0.415861 radiación uvb 0.414555 Instituto Nacional 0.431398 PDQ Tratamiento 0.451873 antecedentes familiares 0.589915 llamada genes ras 0.432872 explorador tep 0.430081 terapia fotodinámica causa 0.453098 sistema nervioso central 0.604707 Physician Data Query 0.464236 mayores probabilidades 0.416225 HCL multisistémica 0.966875 terapia fotodinámica llamada 0.451949 radiación ultravioleta 0.561342 siguientes pruebas 0.489919	CLICK HERE
2036	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	siguientes procedimientos 0.417826 células madre 0.649424 siguientes aspectos 0.405563 leucemia aguda 0.417682 cuerpo.ampliar trasplante 0.403016 hueso compacto 0.418199 genes mpl 0.404719 enlace drugs approved 0.416336 célula madre mieloide 0.431519 genes jak2 0.404899 Sudores nocturnos 0.404299 células anormales.ampliar aspiración 0.420044 National Cancer Institute 0.401966 siguientes riesgos 0.401801 Instituto Nacional 0.403647 célula madre linfoide 0.432844	PDQ Tratamiento 0.431983 leucemia mielógena 0.471893 Drugs Approved 0.417258 Physician Data Query 0.407937 llamada mielofibrosis 0.427648 serios problemas 0.403469 Myeloproliferative Neoplasms 0.417257 siguientes sustancias 0.403598 policitemia vera 0.696975 leucemia mieloide aguda 0.414565 gen jak2 0.405058 célula madre 0.501376 células sanguíneas maduras 0.468721 neoplasias mieloproliferativas 0.925417 siguientes pruebas 0.407534	CLICK HERE
3518	National Cancer Institute	Html	en	Use of Placebos	Information about placebos and their role in cancer clinical trials.	new treatment 0.545554 study 0.364583 patients 0.362034 medicine 0.367624 way 0.414648 treatment group 0.529513 to. 0.361225	doctors 0.371883 treatment clinical trials 0.815475 bias 0.382394 Placebos 0.570523 standard treatment 0.968379 cancer 0.37398	CLICK HERE
3676	National Cancer Institute	Html	en	Genomic Data Access	Information for NIH staff and extramural investigators on how to get a dbGaP account and how to request controlled-access data.	Supplementary Instructions 0.508326 trainees 0.351501 data use limitations 0.53645 access request form 0.751577 permanent employees 0.518968 cancer genotype-phenotype studies 0.653287 dbgap datasets 0.7932 Laboratory staff 0.513494 dbGaP Project Request 0.758272 Minimum Qualifications 0.520392 institution 0.370914 staff member 0.507438 database 0.339571 oversight 0.341561 responsibilities 0.337646 Extramural investigators 0.646629 postdoctoral fellows 0.532793 eRA Commons 0.541518 Applicants 0.337875 laboratory administration 0.514783 data access request 0.968754 NIH staff 0.519235 PIs 0.358599	tenure-track professor 0.518153 NCI Data Access 0.741329 signature approvals 0.518117 Eligibility requirements 0.511168 results 0.339375 email 0.333649 dbGaP Authorized Access 0.761069 seniorscientist 0.335515 Access Individual-Level Data 0.77002 principal investigators 0.705009 genotypes 0.422884 pre-existing account 0.549785 data access requests 0.732725 dbGaP Request Procedures 0.709981 graduate students 0.515113 phenotypes 0.420428 DAR 0.341157 access permission form 0.755217 project requests 0.50912 Investigators Requesting Authorized 0.770653 interaction 0.333238 access form 0.569266 online 0.337555	CLICK HERE
15640	National Cancer Institute	Html	null	Research & Development (R&D) Contracts	null			CLICK HERE